Extensive reforms are being carried out in the pharmaceutical sector in Uzbekistan. This was reported by Zamin.uz.
The main goal of these reforms is to simplify the import of medicines and accelerate the state registration processes. These changes are aimed at improving the system for delivering quality medicines to the population and aligning the national pharmaceutical system with international standards.
At the core of the reforms is a technology transfer mechanism. This mechanism allows foreign pharmaceutical companies to establish production in Uzbekistan and quickly register their products.
As a result, the supply of medicines in the domestic market will increase and export potential will be strengthened. Significant changes are also being made in bringing generic drugs to the market.
Their clinical trials are conducted in accordance with international standards, which ensures faster delivery of medicines to consumers. Additionally, necessary conditions are being created to introduce advanced biotechnological cell preparations into practice.
According to Alisher Temirov, head of the Pharmaceutical Product Safety Center, a differential registration system for medicines has been introduced based on safety levels. The review period for applications for the safest medicines has been reduced from 150 days to 60 days.
For products with a second level of safety, this period is 90 days, and for those in a relatively hazardous category, it is 120 days. Sterile and non-invasive products belonging to the first safety class have been exempted from laboratory and clinical trials.
These measures are aimed at ensuring the population is provided with safe and quality medicines and facilitating the import of certified products. At the same time, since the development and market introduction of a new original drug requires 10-15 years and significant funds, it is natural that innovative drugs are much more expensive than generic drugs.
You can read more detailed information on the one.uz website.
